A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer

Trial Profile

A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Apr 2017

At a glance

  • Drugs Binimetinib (Primary) ; Panitumumab
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Array BioPharma; Novartis Pharmaceuticals
  • Most Recent Events

    • 01 Jun 2016 The trial was prematurely ended in Italy (end date: 2016-01-25).
    • 10 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Sep 2015 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top